Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ligand Pharmaceuticals Inc (LGND)
Price$287.56Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M | $163.6M | $120.3M | $251.5M | $141.1M | $109.0M | $71.9M | $64.5M | $49.0M | $31.4M | $30.0M | $23.5M | $38.9M |
| Gross profit | $253.5M | $156.1M | $120.8M | $143.4M | — | — | — | $245.1M | $135.7M | $103.4M | $66.1M | $55.4M | $43.2M | $27.8M | $25.1M | — | — |
| Gross margin | 94.57% | 93.37% | 91.99% | 73.08% | — | — | — | 97.48% | 96.20% | 94.89% | 91.93% | 85.84% | 88.30% | 88.53% | 83.66% | — | — |
| Research & development | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M | $40.5M | $55.9M | $27.9M | $26.9M | $21.2M | $11.0M | $9.7M | $9.3M | $10.8M | $10.3M | $22.1M | $39.9M |
| Operating expenses | $227.1M | $189.7M | $121.5M | $193.2M | $137.7M | $143.2M | $126.0M | $87.7M | $73.0M | $65.1M | $44.6M | $44.9M | $34.0M | $31.2M | $32.6M | $54.5M | $70.8M |
| Operating income | $41.0M | −$22.6M | $11.9M | $3.0M | $103.9M | $37.5M | $807.1M | $163.7M | $68.1M | $43.9M | $27.3M | $19.6M | $14.9M | $193,000 | −$878,000 | −$29.3M | −$10.0M |
| Operating margin | 15.29% | −13.53% | 9.09% | 1.55% | 42.99% | 22.93% | 670.99% | 65.11% | 48.25% | 40.27% | 38.00% | 30.41% | 30.51% | 0.61% | −2.92% | −124.50% | −25.60% |
| EBITDA | $74.8M | $12.6M | $48.5M | $54.6M | $154.9M | $63.2M | $825.4M | $176.5M | $79.0M | $55.2M | $30.0M | $22.3M | $17.6M | $2.9M | $1.9M | −$27.1M | −$5.3M |
| EBITDA margin | 27.89% | 7.56% | 36.91% | 27.81% | 64.14% | 38.63% | 686.25% | 70.20% | 56.01% | 50.63% | 41.66% | 34.53% | 35.95% | 9.30% | 6.37% | −115.10% | −13.70% |
| Net income | $124.5M | −$4.0M | $52.2M | −$33.4M | $57.1M | −$3.0M | $629.3M | $143.3M | $12.6M | −$1.6M | $229.8M | $12.0M | $11.4M | −$527,000 | $9.7M | −$10.4M | −$1.9M |
| Net profit margin | 46.42% | −2.41% | 39.72% | −17.00% | 23.66% | −1.82% | 523.19% | 57.00% | 8.90% | −1.50% | 319.58% | 18.63% | 23.32% | −1.68% | 32.34% | −44.07% | −5.00% |
| Basic EPSper basic share | $6.44 | -$0.22 | $3.02 | -$1.98 | $3.44 | -$0.18 | $33.13 | $6.77 | $0.60 | -$0.08 | $11.61 | $0.59 | $0.56 | -$0.03 | $0.49 | -$0.53 | -$0.10 |
| Diluted EPSper diluted share | $6.13 | -$0.22 | $2.94 | -$1.98 | $3.31 | -$0.18 | $31.85 | $5.96 | $0.53 | -$0.08 | $10.83 | $0.56 | $0.55 | -$0.03 | $0.49 | -$0.53 | -$0.10 |
Owners
Reported shareholders
15.57%of listed shares
BlackRock, Inc.3.1M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 15.57%3.1M shares |
Invesco Ltd. | 6.03%1.2M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.71%1.14M shares |
Jupiter Topco LLC | 5.22%1.04M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.37%870.95K shares |
STATE STREET CORP | 4.15%826.54K shares |
FMR LLC | 3.83%762.83K shares |
FRANKLIN RESOURCES INC | 3.78%752.04K shares |
CONGRESS ASSET MANAGEMENT CO | 3.31%659.91K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.96%589.02K shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.85%568.37K shares |
Chicago Capital, LLC | 2.78%553.44K shares |
Stephens Investment Management Group LLC | 2.39%475.61K shares |
DIMENSIONAL FUND ADVISORS LP | 2.16%429.31K shares |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.89%375.76K shares |
GOLDMAN SACHS GROUP INC | 1.62%323.25K shares |
LOOMIS SAYLES & CO L P | 1.46%291.81K shares |
RICE HALL JAMES & ASSOCIATES, LLC | 1.36%270.05K shares |
Ranger Investment Management, L.P. | 1.29%257.6K shares |
NORTHERN TRUST CORP | 1.29%257.39K shares |
Percentages use 19.92M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | Sabba Stephen LDirector | SellCommon Stock | 2.1K | $254.00 | $544.8K | 33.6K |
| Jun 12, 2026Form 4 | Haas JasonDirector | SellCommon Stock | 3.5K | $256.08 | $886.3K | 5.0K |
| Jun 12, 2026Form 4 | Haas JasonDirector | SellCommon Stock | 3.0K | $255.01 | $765.0K | 8.4K |
| Jun 11, 2026Form 4 | Aryeh JasonDirector | SellCommon Stock | 4.5K | $250.00 | $1.13M | 102.6K |
| Jun 10, 2026Form 4 | Aryeh JasonDirector | SellCommon Stock | 500 | $250.00 | $125.0K | 107.1K |